Major Shareholding Notification • Feb 12, 2018
Major Shareholding Notification
Open in ViewerOpens in native device viewer
Regulated information
Brussels, Belgium, 12 February 2018, 7.30 pm (CET) – ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 9 February, 2018, the result of which is - following a capital increase completed on 25 January 2019 - that SA SFPI now has 8.87% of the Company's voting rights, and has thus decreased its stake below the 10% threshold.
The statement dated 9 February 2018 notably includes the following information:
Passive crossing of a threshold
Notification by
A parent undertaking or a controlling person
Person subject to the notification requirement
SFPI SA – Avenue Louise 32 b4, 1050 Brussels, Belgium Etat Belge – Rue de la Loi 12, 1000 Brussels, Belgium
Date of the transaction
25 January 2018
Threshold crossed (%)
Downward crossing of the 10% threshold.
Denominator
A total of 15,262,544 voting rights
This notification is available on ASIT biotech's website, in the Documentation / Regulated information section:
https://www.asitbiotech.com/fr/investisseurs/documentation
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.
ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at www.asitbiotech.com.
Company Thierry Legon, CEO ASIT biotech Tel.: +32 2 264 03 90 [email protected]
.
Media and Investor Relations - France NewCap Dusan Oresansky / Pierre Laurent Tel.: +33 1 44 71 94 92 [email protected]
Laure-Eve Monfort Tel.: +32 2 290 90 93 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.